Specialties

Rheumatology (Board certified since 2006)

Internal Medicine (Board certified since 2004)

At a Glance

  • 2007 Started practicing
  • 10 Years experience
  • 1 OFFICE LOCATION
  • 2 HOSPITAL AFFILIATIONS

About Dr. Gizinski

My Clinical Interests

  • arthritis
  • autoimmune disease
  • gout
  • immune disorders
  • lupus erythematosus
  • osteoarthritis
  • polymyalgia
  • Reiter's syndrome
  • sarcoidosis
  • scleroderma
  • vasculitis

Academic Profile

Training

MEDICAL SCHOOL

Washington University School of Medicine, Seattle, WA
2001

INTERNSHIP

Univeristy of Colorado School of Medicine, Aurora, CO
2002

RESIDENCY

Univeristy of Colorado School of Medicine, Aurora, CO
2004

FELLOWSHIP

Univeristy of Colorado School of Medicine, Aurora, CO
2007

Professional Memberships

American College of Rheumatology

American College of Physiians

Major Publications

Gizinski AM, Nelson JL Maternal HLA Compatibility as a Risk Factor for Systemic Lupus Erythematosus in Males. Journal of Investigative Medicine 1999, 47(2), 74A.

Gizinski AM, Kervitsky D, Meehan R. Brown KK, Holers VM, Deane KD. Rheumatoid Arthritis-Specific Autoantibodies Are Present in Patients with Interstitial Lung Disease in the Absence of Arthritis. Journal of Investigative Medicine 2007, 55(416), S144.

Gizinski AM, Mascolo M, Loucks JL, Kervitsky A, Meehan RT. Brown KK, Holers VM, Deane KO. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009 May; 28(5):611-3. doi: 10.1007/s10067-009-1128-9. Epub 2009 Feb 28. PubMed PMID: 19252818; PubMed Central PMCID: PMC4084723.

Fox DA, Gizinski A, Morgan R, Lundy SK. Cell-cell interactions in rheumatoid arthritis synovium. Rheum Dis Clin North Am. 2010 May; 36(2):311-23. doi: 10.1016/j.rdc.2010.02.004. Review. PubMed PMID: 20510236; PubMed Central PMCID: PMC2879397.

Gizinski AM, Fox DA, Sarkar S. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol. 2010 Aug; 24(4):463-77. doi: 10.1016/j.berh.2009.12.015. Review. PubMed PMID: 20732645; PubMed Central-PMCID: PMC3146352.

Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L. Robinson WH, Arend WP, Thompson PR, Holers VM. N-a­benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a_ protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J lmmunol. 2011 Apr 1; 186(7):4396-404. doi: 10.4049/jimmunol.1001620. Epub 2011 Feb 23. PubMed PMID: 21346230; PubMed Central PMCID: ·PMC3085980.

Keith RC, Powers JL, Redente EF, Sergew A, Martin RJ, Gizinski A, Holers VM, Sakaguchi S, Riches OW. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice. Exp Lung Res. 2012 Mar;38(2):55-66. doi: 10.3109/01902148.2011.636139. Epub 2011 Dec 20. PubMed PMID: 22185348. 

Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A. Gizinski A, Yalavarthi S, Knight JS, Friday S, Li S, Patel RM, Subramanian V, Thompson P, Chen P, Fox DA, Pennathur S, Kaplan MJ. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013 Mar 27; 5{178):178ra40. doi: 10.1126/scitranslmed.3005580. PubMed PMID: 23536012; PubMed Central PMCID: PMC3727661.

Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol. 2014 Mar;26{2):204-10. doi: 10.1097/BOR.0000000000000036. Review. PubMed PMID: 24445478.

Book Chapter

Gizinski AM, Fox DA. Emerging Therapeutic Targets; IL-15, I L-17. IL-18 and I L-23. RHEUMATOLOGY, Fifth Edition edited by Marc C. Hochberg, MD, Alan J. Silman, MSC, MO, FRCP, FMEDSCI, Josef S. Smolen, MD, Michael E. Weinblatt, MD, and Michael H. Weisman, MD. 2010. ISBN: 978- 0-323-05740-0  

Lundy SK, Fox DA, Gizinski A Introduction to clinical-immunology: overview of the immune response, autoimmune conditions, and immunosuppressive therapeutics. In: Nabel EG, editor. ACP Medicine: Allergy & Immunology. Hamilton, ON: Decker_ Publishing; 2012. p. 1-15.

Gizinski AM, Fo.x: DA. Chapter 65 Emerging therapeutic targets: GM-CSF, IL-17and ll·23. RHEUMATOLOGY, Sixth Edition edited by Marc C. Hochberg, MD MPH, Alan J. Silman, MSC, MD, FRCP, FMEDSCI, Josef S. Smolen, MD, Michael E. Weinblatt, MD, and MichaelH. Weisman, MD. July 2014. ISBN: 978-0-323,09138-1

Lundy SK, Fox DA, Gizinski A. Introduction to Clinical Immunology: Overview of the Immune Response, Autoimmune Conditions, and lmmunosuppressive Therapeutics for Rheumatic Diseases. Scientific American Medicine. Singh AK, editor. May 2016. ISSN: 2292-597X.

Locations & Appointments

1 Office Location(s)

1

Emory Clinic 'A'

Emory Clinic at 1365 Clifton Rd
1365 Clifton Rd NE
Fl 3
Atlanta, GA 30322
  • 404-778-4366
S

2 Hospital Affiliation(s)

2

Emory University Hospital

1364 Clifton Rd NE
Atlanta, GA 30322
H
3

Emory University Hospital Midtown

550 Peachtree St NE
Atlanta, GA 30308
H

Academic Profile

Training

MEDICAL SCHOOL

Washington University School of Medicine, Seattle, WA
2001

INTERNSHIP

Univeristy of Colorado School of Medicine, Aurora, CO
2002

RESIDENCY

Univeristy of Colorado School of Medicine, Aurora, CO
2004

FELLOWSHIP

Univeristy of Colorado School of Medicine, Aurora, CO
2007

Professional Memberships

American College of Rheumatology

American College of Physiians

Major Publications

Gizinski AM, Nelson JL Maternal HLA Compatibility as a Risk Factor for Systemic Lupus Erythematosus in Males. Journal of Investigative Medicine 1999, 47(2), 74A.

Gizinski AM, Kervitsky D, Meehan R. Brown KK, Holers VM, Deane KD. Rheumatoid Arthritis-Specific Autoantibodies Are Present in Patients with Interstitial Lung Disease in the Absence of Arthritis. Journal of Investigative Medicine 2007, 55(416), S144.

Gizinski AM, Mascolo M, Loucks JL, Kervitsky A, Meehan RT. Brown KK, Holers VM, Deane KO. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009 May; 28(5):611-3. doi: 10.1007/s10067-009-1128-9. Epub 2009 Feb 28. PubMed PMID: 19252818; PubMed Central PMCID: PMC4084723.

Fox DA, Gizinski A, Morgan R, Lundy SK. Cell-cell interactions in rheumatoid arthritis synovium. Rheum Dis Clin North Am. 2010 May; 36(2):311-23. doi: 10.1016/j.rdc.2010.02.004. Review. PubMed PMID: 20510236; PubMed Central PMCID: PMC2879397.

Gizinski AM, Fox DA, Sarkar S. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol. 2010 Aug; 24(4):463-77. doi: 10.1016/j.berh.2009.12.015. Review. PubMed PMID: 20732645; PubMed Central-PMCID: PMC3146352.

Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L. Robinson WH, Arend WP, Thompson PR, Holers VM. N-a­benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a_ protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J lmmunol. 2011 Apr 1; 186(7):4396-404. doi: 10.4049/jimmunol.1001620. Epub 2011 Feb 23. PubMed PMID: 21346230; PubMed Central PMCID: ·PMC3085980.

Keith RC, Powers JL, Redente EF, Sergew A, Martin RJ, Gizinski A, Holers VM, Sakaguchi S, Riches OW. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice. Exp Lung Res. 2012 Mar;38(2):55-66. doi: 10.3109/01902148.2011.636139. Epub 2011 Dec 20. PubMed PMID: 22185348. 

Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A. Gizinski A, Yalavarthi S, Knight JS, Friday S, Li S, Patel RM, Subramanian V, Thompson P, Chen P, Fox DA, Pennathur S, Kaplan MJ. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013 Mar 27; 5{178):178ra40. doi: 10.1126/scitranslmed.3005580. PubMed PMID: 23536012; PubMed Central PMCID: PMC3727661.

Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol. 2014 Mar;26{2):204-10. doi: 10.1097/BOR.0000000000000036. Review. PubMed PMID: 24445478.

Book Chapter

Gizinski AM, Fox DA. Emerging Therapeutic Targets; IL-15, I L-17. IL-18 and I L-23. RHEUMATOLOGY, Fifth Edition edited by Marc C. Hochberg, MD, Alan J. Silman, MSC, MO, FRCP, FMEDSCI, Josef S. Smolen, MD, Michael E. Weinblatt, MD, and Michael H. Weisman, MD. 2010. ISBN: 978- 0-323-05740-0  

Lundy SK, Fox DA, Gizinski A Introduction to clinical-immunology: overview of the immune response, autoimmune conditions, and immunosuppressive therapeutics. In: Nabel EG, editor. ACP Medicine: Allergy & Immunology. Hamilton, ON: Decker_ Publishing; 2012. p. 1-15.

Gizinski AM, Fo.x: DA. Chapter 65 Emerging therapeutic targets: GM-CSF, IL-17and ll·23. RHEUMATOLOGY, Sixth Edition edited by Marc C. Hochberg, MD MPH, Alan J. Silman, MSC, MD, FRCP, FMEDSCI, Josef S. Smolen, MD, Michael E. Weinblatt, MD, and MichaelH. Weisman, MD. July 2014. ISBN: 978-0-323,09138-1

Lundy SK, Fox DA, Gizinski A. Introduction to Clinical Immunology: Overview of the Immune Response, Autoimmune Conditions, and lmmunosuppressive Therapeutics for Rheumatic Diseases. Scientific American Medicine. Singh AK, editor. May 2016. ISSN: 2292-597X.